Ashwagandha could help fight COVID-19, says IIT-Delhi
Indian Institute of Technology, Delhi (IIT-D) and National Institute of Advanced Industrial
Science and Technology, Japan in a collaborative study discovered that Ashwagandha may hold
an efficient natural compound that could be effective in developing a drug for the coronavirus.
The researchers discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester (CAPE), an active ingredient of New Zealand propolis, has the potential to interact with and block the activity of Mpro.
According to the team, the findings will save time and cost required for screening of anti-COVID-19 drugs and will also offer some preventive and therapeutic value for the management of the fatal 19 pandemic. Hence they warrant prioritised validation in laboratory and clinical tests.
“The drug development may take a while and in the current scenario, these natural resources (Ashwagandha and Propolis) may offer some preventive or even therapeutic value. However, although they are easily available and affordable, one has to be cautious about the content of bioactive ingredients. CAPE, while is a major component of propolis, its amount and stability are critical factors that could be managed by generating its complex with cyclodextrins,” said a scientist.
Prof. D. Sundar, coordinator of DAILAB, IIT-D and Head of the Department of Biochemical Engineering and Biotechnology said, “The traditional medicine system ‘Ayurveda’ has been practised for thousands of years in India. Unlike modern medicine, the mechanism of action of natural drugs has not been resolved so far. IIT-Delhi and AIST researchers have been working together for more than a decade and trying to contribute to strengthening this avenue by merging the traditional knowledge with modern technologies.”
A potential game changer?
The researchers discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester, an active ingredient of New Zealand propolis, has the potential to interact with and block the activity of Mpro.
Science and Technology, Japan in a collaborative study discovered that Ashwagandha may hold
an efficient natural compound that could be effective in developing a drug for the coronavirus.
The researchers discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester (CAPE), an active ingredient of New Zealand propolis, has the potential to interact with and block the activity of Mpro.
According to the team, the findings will save time and cost required for screening of anti-COVID-19 drugs and will also offer some preventive and therapeutic value for the management of the fatal 19 pandemic. Hence they warrant prioritised validation in laboratory and clinical tests.
“The drug development may take a while and in the current scenario, these natural resources (Ashwagandha and Propolis) may offer some preventive or even therapeutic value. However, although they are easily available and affordable, one has to be cautious about the content of bioactive ingredients. CAPE, while is a major component of propolis, its amount and stability are critical factors that could be managed by generating its complex with cyclodextrins,” said a scientist.
Prof. D. Sundar, coordinator of DAILAB, IIT-D and Head of the Department of Biochemical Engineering and Biotechnology said, “The traditional medicine system ‘Ayurveda’ has been practised for thousands of years in India. Unlike modern medicine, the mechanism of action of natural drugs has not been resolved so far. IIT-Delhi and AIST researchers have been working together for more than a decade and trying to contribute to strengthening this avenue by merging the traditional knowledge with modern technologies.”
A potential game changer?
The researchers discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester, an active ingredient of New Zealand propolis, has the potential to interact with and block the activity of Mpro.
T